You are here: Industry Insights > CLL

News List

Ibrutinib, Venetoclax Active in High-Risk, Seniors With CLL drugs
May 31, 2019
Ibrutinib, Venetoclax Active in High-Risk, Seniors With CLL.
Roche receives FDA approval for Venclexta plus Gazyva in CLL pharmaceutical-technology
May 22, 2019
Roche has obtained approval by the US Food and Drug Administration (FDA) for Venclexta (venetoclax) and Gazyva (obinutuzumab) to treat chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
AZ’ Calquence trial to stop early after hitting endpoints pharmatimes
May 09, 2019
AZ’ Calquence trial to stop early after hitting endpoints.
Celgene’s luspatercept aces phase 3 beta thalassemia trial fiercebiotech
January 03, 2019
A phase 3 trial of Celgene’s luspatercept in adults with beta thalassemia has hit its primary goal. The late-phase success tees Celgene to file for approval of its Acceleron-partnered blockbuster prospect in the first half of next year......
ASH: Ibrutinib Tops Bendamustine + Rituximab for CLL drugs
December 04, 2018
For older patients with untreated chronic lymphocytic leukemia (CLL), treatment with ibrutinib alone or in combination with rituximab is associated with improved.....
Invectys raises €15M for DNA cancer vaccine study in CLL fiercepharma
November 28, 2018
French startup Invectys hopes its cancer vaccine can win a spot in immuno-oncology combination therapies, and it just nabbed €15 million ($17 million) in series A funding to support that ambition.
NICE issues draft guidance rejecting Abbvie's Venclyxto in chronic lymphocytic leukaemia pharmafile
October 31, 2018
It’s bad news for patients in the UK affected by chronic lymphocytic leukaemia (CLL) as the National Institute of Health and Care Excellence (NICE) has announced its decision not to ...
Roche’s Venclexta filed in the US for acute myeloid leukemia pharmatimes
July 13, 2018
Roche group Genentech has filed an application to market Venclexta in the US for acute myeloid leukemia (AML).
AbbVie eyes Imbruvica expansion in CLL as Gazyva pairing hits its marks fiercepharma
May 28, 2018
AbbVie’s Imbruvica growth strategy in chronic lymphocytic leukemia centers on expanding use of the drug among previously untreated patients. And it now has some new data that should help it do that.
SMC approves Amgen’s carfilzomib for multiple myeloma treatment pharmaceutical-technology
August 10, 2017
The Scottish Medicines Consortium (SMC) has approved the routine use of Amgen’s carfilzomib (Kyprolis), in combination with dexamethasone, for the treatment of multiple myeloma across National Health Service (NHS) Scotland.

Previous page 1 2 3 4 Next page